Research & Innovation
At Dana-Farber/Children’s Hospital Cancer Center, our care is informed by our research. We have a long history of research and innovation in treating childhood cancers.
Children's Hospital and Dana-Farber are conducting numerous research studies that will help clinicians better understand and treat soft tissue sarcomas, including studying:
angiogenesis inhibitors—substances that may be able to prevent the growth of tumors
biological therapies—substances that may be able to involve the body’s own immune system to fight cancer or lessen harmful side effects of some treatments
neoadjuvant chemotherapy and radiotherapy, which may reduce the incidence of metastatic disease
We are a world leader in opening new avenues of "translational research," bringing laboratory advances to the bedside and doctor's office as quickly as possible. All of our senior medical staff members of the Bone and Soft Tissue Tumors Program participate in clinical research activities. Our program director, Carlos Rodriguez-Galindo, MD, is also the co-director of our new Clinical and Translational Investigation Program, which aims to dramatically improve translational research in pediatric hematology and oncology.
In addition to a variety of clinical trials, we also conduct extensive laboratory research to identify new treatments and improve therapies for bone and soft tissue tumors.
Read all about our innovative approach at Dana-Farber/Children’s Hospital Cancer Center.
For more information about current research on bone tumors, visit our Bone & Soft Tissue Tumor Program page.
|Find out more about the innovative clinical trials available at Boston Children's Hospital and Dana Farber.|